Preclinical Phase Articles & Analysis
16 news found
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded ...
Other candidates have already been constructed and are undergoing preclinical evaluation, against HPV induced cancers or infectious diseases. ...
ByOncoVITA
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...
Dirbas will serve as Chair of the SAB, which provides guidance for ongoing preclinical studies as well as ongoing and planned future clinical trials in the use of UNO to treat solid tumors. ...
Our lead compound, OLX-07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program, will start Phase 1 clinical studies in the first half of 2022. ...
Immunology We have built up over 20 years of expertise in immunology, resulting in a deep and growing pipeline with multiple modes-of-action candidate medicines across all phases of development, from preclinical to Phase 4. We are excited about our selective TYK2 inhibitor, ‘3667, for which we presented new data elucidating its ...
It is highly encouraged to start this forced degradation testing and analysis early in the preclinical phase or phase I of clinical trials. This will help gain sufficient time for identifying degradation products and structure elucidation. ...
Cancer Research UK’s Centre for Drug Development (CDD) is managing and providing significant funding for the phase I/IIa trial. Vaccitech Oncology Limited (VOLT), a strategic collaboration between Vaccitech and Ludwig, are supplying VTP-600 for the trial. ...
The company also secured funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator to evaluate their device for predictive diagnosis of Alzheimer’s in the preclinical phase, and from Eisai Innovation, a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of ...
It follows INOVIO's pre-clinical and Phase 1 trials which suggested to investigators that INO-4201 was well-tolerated and resulted in 100% seroconversion after two doses. "We are excited to begin this Phase 1b trial with our intradermal DNA vaccine candidate INO-4201 as a potential Ebola booster vaccine," said Laurent Humeau, Ph.D., Chief Scientific Officer, ...
Additionally, it provides a pathway for accelerated approval and rolling review of completed Biological Licensing Application sections by the FDA. TVAX Biomedical has completed phase 1/2a studies in multiple cancers, including GBM. Significant efficacy was demonstrated in GBM patients using TVAX’s patented vaccineenhanced adoptive T cell therapy (VACT) in those studies. ...
Wayne Carter as president and chief executive officer effective immediately. TVAX Biomedical is planning phase 2 clinical studies for glioblastoma multiforme, an orphan disease for which there is no effective treatment. ...
This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. Such lesions are rare but can have serious consequences for patients. This hepatotoxic potential is poorly detected by current preclinical models. Beyond animal models, various models based on human cell cultures are available, ...
ByPoietis
Thanks to IMX313, Imaxio is currently developing a clinical-stage pipeline composed of several vaccine candidates indicated to prevent or treat malaria (phase I), influenza (preclinical phase), and some types of cancer (research). ...
” BloodCenter of Wisconsin’s Clinical Trials and Cellular Therapy Services provide a full spectrum of services for clinical trials (preclinical and phases I–IV) in a wide range of therapeutic areas. ...
Cambridge, UK, 8th February 2016 – Biosceptre, a biopharmaceutical company developing innovative diagnostic and therapeutic approaches to cancer, today announced that the UK government-backed Innovate UK SMART award scheme, has awarded the company £100,000 to support pre-clinical development of diagnostic approaches and antibodies to target Kidney and Lung cancers. This project will ...